Shares of Torrent Pharmaceuticals are likely to remain in focus after an Indian government-appointed committee accepted the company’s Phase III clinical trial (CT) study report for Semaglutide tablets.
Government panel accepts Phase III study
According to the update, the committee has reviewed and accepted Torrent Pharmaceuticals’ Phase III clinical trial data for Semaglutide. Following this, the panel has recommended granting permission to manufacture and market Semaglutide tablets in India.
This marks a key regulatory milestone for the company, bringing it closer to commercialising the product, subject to final approvals from the relevant authorities.
Recommendation to manufacture and market Semaglutide
The committee’s recommendation allows Torrent Pharmaceuticals to move ahead with plans to manufacture and market Semaglutide tablets in the domestic market. The development is significant given the growing demand for advanced therapies in metabolic disorders.
About Semaglutide
Semaglutide is primarily used for the treatment of controlled type-2 diabetes. The drug belongs to the GLP-1 receptor agonist class and is widely prescribed to help improve glycaemic control in adults with type-2 diabetes.
With the acceptance of the Phase III data and the recommendation in place, Torrent Pharmaceuticals’ progress on Semaglutide is being closely tracked by the market, keeping the stock firmly in focus.
